CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Oric Pharmaceuticals
ORIC
$1.09B
| $79.5K | 0.01% |
14,247
-716
| -5% | -$4K |
|
377
SIGA Technologies
SIGA
$599M
| $78.5K | 0.01% |
14,323
-817
| -5% | -$4.48K |
|
378
Tourmaline Bio
TRML
$700M
| $78.2K | 0.01% |
5,143
-294
| -5% | -$4.47K |
|
379
Erasca
ERAS
$440M
| $77.7K | 0.01% |
56,710
-3,239
| -5% | -$4.44K |
|
380
Altimmune
ALT
$322M
| $77.2K | 0.01% |
15,448
+367
| +2% | +$1.84K |
|
|
ORKA
381
Oruka Therapeutics, Inc. Common Stock
ORKA
$600M
| $77K | 0.01% |
7,509
+88
| +1% | +$903 |
|
382
Sana Biotechnology
SANA
$757M
| $75.2K | 0.01% |
44,784
-2,557
| -5% | -$4.3K |
|
|
BCYC
383
Bicycle Therapeutics
BCYC
$494M
| $75K | 0.01% |
8,833
-496
| -5% | -$4.21K |
|
384
CorMedix
CRMD
$956M
| $75K | 0.01% |
12,171
-695
| -5% | -$4.28K |
|
385
EyePoint Pharmaceuticals
EYPT
$975M
| $74.2K | 0.01% |
13,690
-782
| -5% | -$4.24K |
|
386
Galapagos
GLPG
$2.2B
| $73.6K | 0.01% |
2,931
-31
| -1% | -$779 |
|
|
RAPP
387
Rapport Therapeutics
RAPP
$579M
| $73.6K | 0.01% |
7,337
-419
| -5% | -$4.2K |
|
388
Regenxbio
RGNX
$501M
| $71.1K | 0.01% |
9,938
-567
| -5% | -$4.05K |
|
389
Stoke Therapeutics
STOK
$1.12B
| $70.7K | 0.01% |
10,624
-607
| -5% | -$4.04K |
|
390
Entrada Therapeutics
TRDA
$208M
| $68.2K | 0.01% |
7,541
-390
| -5% | -$3.53K |
|
391
Cartesian Therapeutics
RNAC
$278M
| $67.2K | 0.01% |
5,098
-291
| -5% | -$3.84K |
|
392
Pacific Biosciences
PACB
$375M
| $67.1K | 0.01% |
56,851
-3,137
| -5% | -$3.7K |
|
393
First Trust Dow Jones Internet Index Fund ETF
FDN
$7.3B
| $66.6K | 0.01% |
+300
| New | +$66.6K |
|
394
First Trust Cloud Computing ETF
SKYY
$3.07B
| $66.5K | 0.01% |
+650
| New | +$66.5K |
|
395
Rigel Pharmaceuticals
RIGL
$723M
| $63.6K | 0.01% |
3,533
-202
| -5% | -$3.63K |
|
396
Maravai LifeSciences
MRVI
$362M
| $62.9K | 0.01% |
28,451
-1,625
| -5% | -$3.59K |
|
|
AUTL
397
Autolus Therapeutics
AUTL
$381M
| $62.3K | 0.01% |
40,200
-2,145
| -5% | -$3.33K |
|
398
Personalis
PSNL
$458M
| $62.1K | 0.01% |
17,704
+2,724
| +18% | +$9.56K |
|
399
Allogene Therapeutics
ALLO
$257M
| $61.4K | 0.01% |
42,057
-2,401
| -5% | -$3.51K |
|
400
Amylyx Pharmaceuticals
AMLX
$891M
| $60.8K | 0.01% |
17,188
+2,653
| +18% | +$9.39K |
|